A recent House Committee hearing on capital markets and China took on the question of sanctions and delisting. Is there more to come?
A Boston Celtics player gets the NBA team in trouble in China. But Enes Kanter is showing companies what is truly at stake if they dare go against a CCP narrative.
A House Foreign Affairs Committee hearing this week on climate change discusses the prevalence of green finance. And a growing distrust over China’s commitments and its solar supply chain, especially in Xinjiang.
A House committee hearing on the impact of the supply crisis on small businesses left out one key solution: import less, make more here.
A senior Chinese official told the U.S. China Business Council that the U.S. and China should partner on EVs and biotech. The private sector can do what it wants. But Washington should not take Beijing up on this offer.
An Indian drug market that’s been the subject of FDA warnings since 2017 is the apparent source of tainted medication sold in the U.S. and Canada. This is another example as to why we need to reshore critical supply of essential medication. Where is Congress?
Task Force Argo’s latest $1.1 million evacuation mission in Afghanistan was largely funded by CPA member Zekelman Industries.
China’s energy rationing hurts American supply chains already in trouble. Diversification away from China should continue full speed ahead for anyone concerned with economic security.
The Trump administration refused to approve new trade dispute judges to the WTO. The Biden administration isn’t in any real hurry to fix it.
In speaking for the Biden administration this week at a conference at think tank CSIS in Washington, Katherine Tai said she didn’t want to “inflame relations” with China. Why this attitude gets us nowhere but towards the China-centric, pre-trade war status quo.